A novel immunoliposome drug delivery system comprised of trastuzumab and enediyne natural product tiancimycin A is prepared and evaluated against HER2‐positive breast tumor mouse model, revealing that a single dose of the immunoliposome (0.02 mg kg−1) significantly suppressed the tumor growth without obvious toxicity. This evidence concerns the gene ERBB2 and breast neoplasm.